Annual report [Section 13 and 15(d), not S-K Item 405]

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

v3.25.1
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Series A Convertible Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2022   $ 0 $ 76,369,940 $ (75,734,927) $ 635,013
Beginning balance, shares at Dec. 31, 2022   136      
Issuance of common stock in public offerings, net of issuance costs of $629,900   4,570,085 4,570,085
Issuance of common stock in public offerings, net of issuance costs, shares   42      
Issuance of common stock for exercise of stock options and vesting of restricted stock units   25,000 25,000
Issuance of common stock for exercise of stock options and vesting of restricted stock units, shares   1      
Issuance of common stock units in public offering, net of issuance costs of $28,777   255,505 255,505
Issuance of common stock units in public offering, net of issuance costs, shares   93      
Issuance of pre-funded warrant units, net of issuance costs of $342,071   3,037,121 3,037,121
Issuance of common stock for exercise of pre-funded warrants   8 8
Issuance of common stock for exercise of pre-funded warrants, shares   1,006      
Issuance of common stock for exercise of warrants   680,978 680,978
Issuance of common stock for exercise of warrants, shares   12      
Proceeds received for reduction of warrant exercise price   346,500 346,500
Stock-based compensation   2,627,925 2,627,925
Stock-based compensation, shares   1      
Net loss   (45,071,211) (45,071,211)
Reclassification of derivative liabilities to equity   13,262,055 13,262,055
Ending balance, value at Dec. 31, 2023 $ 0 $ 0 101,175,117 (120,806,138) (19,631,021)
Ending balance, shares at Dec. 31, 2023 0 1,291      
Issuance of common stock for exercise of pre-funded warrants $ 2 (2)
Issuance of common stock for exercise of pre-funded warrants, shares   226,343      
Issuance of common stock for exercise of Series A warrants 17,352,653 17,352,653
Issuance of common stock for exercise of Series A warrants, shares   17,325      
Proceeds received for exercise of buydown warrants 3,500 3,500
Proceeds received for exercise of buydown warrants, shares   10      
Common stock issued for conversion of convertible notes 7,395,907 7,395,907
Common stock issued for conversion of convertible notes, shares   4,971      
Conversion of Convertible Notes for Preferred Stock 24,716,118 24,716,118
Conversion of Convertible Notes for Preferred Stock, shares 24,698        
Conversion of Preferred Stock for common stock $ 3 (3)
Conversion of Preferred Stock for common stock, shares (24,698) 279,043      
Issuance of common stock for exercise of Series B Warrants (1) (1)
Issuance of common stock for exercise of Series B Warrants, shares   14,701      
Reclassification of warrant liability to equity 3,405,662 3,405,662
Proceeds received for issuance of warrants with May 2024 Notes, net of issuance costs of $111,194 1,023,200 1,023,200
Issuance of common stock and pre-funded warrants, net of issuance costs of $1,210,753 $ 1 10,789,260 10,789,261
Issuance of common stock and pre-funded warrants, net of issuance costs, shares   102,605      
Stock-based compensation 310,961 310,961
Exchange of Common Stock for Prefunded Warrants  
Exchange of Common Stock for Prefunded Warrants, shares   (96,821)      
Proceeds from sale of common stock from ATM, net if issuance costs of $112,814   $ 1 184,829   184,830
Proceeds from sale of common stock from ATM, net if issuance costs, shares   68,921      
Common stock issued for reverse stock split due to rounding
Common stock issued for reverse stock split due to rounding, shares   12,476      
Net loss (45,510,309) (45,510,309)
Ending balance, value at Dec. 31, 2024 $ 0 $ 7 $ 166,357,201 $ (166,316,447) $ 40,761
Ending balance, shares at Dec. 31, 2024 0 630,865